Phase 3 results presented at the AAO Annual Meeting demonstrated the IZERVAY treatment effect more than doubled over 2 years compared to 1 year IZERVAY safety profile was consistent with year 1, with no cases of ischemic optic neuropathy or retinal vasculitis Over 2 years, only a slight…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.